Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go
- 30 June 2004
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 50 (3) , 175-186
- https://doi.org/10.1016/j.critrevonc.2004.02.004
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on PrognosisJournal of Clinical Oncology, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- The EGF receptor family as targets for cancer therapyOncogene, 2000
- Cell Signaling by Receptor Tyrosine KinasesPublished by Elsevier ,2000
- The Hallmarks of CancerCell, 2000
- Creation of human tumour cells with defined genetic elementsNature, 1999
- Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosectionsBritish Journal of Cancer, 1996
- Epidermal growth factor stimulates phosphorylation in membrane preparations in vitroNature, 1978